Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Razis, Evangelia ^a   Briasoulis, Evangelos ^b   Vrettou, Eleni ^c   Skarlos, Dimosthenis V ^d   Papamichael, Dimitrios ^e   Kostopoulos, Ioannis ^c   Samantas, Epaminontas ^f   Xanthakis, Ioannis ^c   Bobos, Mattheos ^c   Galanidi, Eleni ^a   Bai, Maria ^b   Gikonti, Ioanna ^g   Koukouma, Alona ^e   Kafiri, Georgia ^h   Papakostas, Pavlos ^h   Kalogeras, Konstantine T ^c,i   Kosmidis, Paris ^a   Fountzilas, George ^c  

^a HYGEIA HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d HENRY DUNANT HOSPITAL   (Greece)

^e Bank of Cyprus Group Oncology Centre   (Cyprus)

^f AGII ANARGIRI CANCER HOSPITAL   (Greece)

^g AGIA OLGA HOSPITAL   (Greece)

^h HIPPOKRATION HOSPITAL   (Greece)

ⁱ Hellenic Cooperative Oncology Group   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PTEN PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; COLON BIOPSY; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; EXPLORATORY RESEARCH; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; SKIN TOXICITY; TISSUE FIXATION; ADENOCARCINOMA; COLORECTAL TUMOR; ENZYMOLOGY; GENE DELETION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 51249089269     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-234     Document Type: Article

References (24)

1. Carpenter G Cohen S: Epidermal growth factor. J Biol Clin 1990, 265:7709-7712.
2. Mayer A Takimoto M Fritz E Schellander G Kofler K Ludwig H: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and mdr gene expression in colorectal cancer. Cancer 1993, 71:2454-2460. 10.1002/ 1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2 8095852
3. Lenz HJ Van-Cutsem E Khambata-Ford S Mayer RJ Gold P Stella P Mirtsching B Cohn AL Pipas AW Azarnia N Tsuchihashi Z Mauro DJ Rowinsky EK: Multicenter phase II and translational study of cetuximab in Metastatic Colorectal Carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. J Clin Oncol 2006, 24:4914-4921. 10.1200/ JCO.2006.06.7595 17050875
4. Saltz LB Kies M Abbruzzesse JL Azarnia N Needle M: The presence and intensity of the cetuximab- induced acne-like rash predicts increased survival in studies across multiple malignances. Proc Am Soc Clin Oncol 2003, 22:204 X(A817)
5. Saltz LB Meropol NT Loehrer PJ Sr Needle MN Kopit J Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208. 10.1200/JCO.2004.10.182 14993230
6. Chung KY Shia J Kemeny NE Shah M Schwartz GK Tse A Hamilton A Pan D Schrag D Schwartz L Klimstra DS Fridman D Kelsen DP Saltz LB: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005, 23:1803-1810. 10.1200/JCO.2005.08.037 15677699
7. Shia J Klimstra DS Li AR Qin J Saltz L Teruya-Feldstein J Akram M Chung KY Yao D Paty PB Gerald W Chen B: Epidermal growth factor receptor expression on gene amplification in colorectal carcinoma. An immunohistochemical and chronogenic in situ hybridization study. Mod Pathol 2005, 18:1350-6. 10.1038/modpathol.3800417 15832190
8. Sauer T Guren ML Noren T Dueland S: Demonstration of EGFR gene copy loss in colorectal carcinoma by fluorescent in situ hybridization (FISH) a surrogate marker for sensitivity to specific anti-EGFR therapy?. Histopathology 2005, 47:560-4. 10.1111/j.1365-2559.2005.02252.x 16324192
9. Moroni M Veronese S Benvenuti S Marrapese G Sartore-Bianchi A Di Nicolantonio F Gambacorta M Siena S Bardelli A: Gene copy number of epidermal growth factor receptor (EGFR) and clinical response to anti EGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 2005, 6:279-286. 10.1016/S1470-2045(05)70102-9 15863375
10. Frattini M Saletti P Romagnani E Martin V Molinari F Ghisletta M Camponovo A Etienne LL Cavalli F Mazzucchelli L: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. British Journal of Cancer 2007, 97:1139-1145. 10.1038/sj.bjc.6604009 17940504
11. Vallböhmer D Zhang W Gordon M Yang DY Yun J Press OA Rhodes KE Sherrod AE Iqbal S Danenberg KD Groshen S Lenz HJ: Molecular determinants of cetuximab efficacy. J Clin Oncol 2005, 23:3536-3544. 10.1200/JCO.2005.09.100 15908664
12. Lievre A Bachet JB Le Corre D Boige V Landi B Emile JF Côté JF Tomasic G Penna C Ducreux M Rougier P Penault-Llorca F Laurent-Puig P: Kras mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2005, 66:3992-3995. 10.1158/ 0008-5472.CAN-06-0191
13. Massarelli E Varella-Garcia M Tang X Xavier AC Ozburn NC Liu DD Bekele BN Herbst RS Wistuba II: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small- cell lung cancer. Clin Cancer Res 13, 10:2890-6. 2007 May 15 10.1158/1078-0432.CCR-06-3043 17504988
14. Luwor RB Lu Y Li X Mendelsohn J Fan Z: The antiepidermal growth factor receptor monoclonal antibody cetuximab/C 225 reduces hypoxia-inducible factor 1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 2005, 24:4433-4441. 10.1038/sj.onc.1208625 15806152
15. Mellinghoff IK Cloughesy TF Mischel PS: PTEN mediated resistance to Epidermal Growth Factor Receptor Kinase inhibitors. Clin Cancer Res 2007, 13(2):370-382. 10.1158/1078-0432.CCR-06-1992
16. Fountzilas G Karkavelas G Kalogera-Fountzila A Karina M Ignatiadis M Koukoulis G Plataniotis G Bobos M Pectasides D Razis E Karavelis A Selviaridis P: Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. Anticancer Res 2006, 26:4675-4686. 17214326
17. Italiano A Saint-Paul MC Caroli-Bosc FX Francois E Bourgeon A Benchimol D Gugenheim J Michiels JF: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: Biological and clinical implications. Ann Oncol 2005, 16:1503-1507. 10.1093/annonc/mdi282 15980160
18. Bredel M Pollack IF Hamilton RL James CD: Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 1999, 5:1786-1792. 10430083
19. Perren A Weng LP Boag AH Ziebold U Thakore K Dahia PL Komminoth P Lees JA Mulligan LM Mutter GL Eng C: Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999, 155:1253-1260. 1867038 10514407
20. Sunpaweravong P Sunpaweravong S Puttawibul P Mitarnun W Zeng C Baron AE Franklin W Said S Varella-Garcia M: Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2005, 131:111-119. 10.1007/s00432-004-0610-7 15672286
21. Mellinghoff IK Wang MI Vivanco I Haas-Kogan DA Zhu S Dia EQ Lu KV Yoshimoto K Huang JH Chute DJ Riggs BL Horvath S Liau LM Cavenee WK Rao PN Beroukhim R Peck TC Lee JC Sellers WR Stokoe D Prados M Cloughesy TF Sawyers CL Mischel PS: Molecular determinants of the response of glioblastomas to EGFR Kinase Inhibitors. N Eng J Med 2005, 353:2012-24. 10.1056/NEJMoa051918
22. She QB Solit DB Ye Q O'Reilly KE Lobo J Rosen N: The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt Kinase pathway in PTEN-deficient tumor cells. Cancer Cell 2005, 8:287-297. 10.1016/ j.ccr.2005.09.006 16226704
23. Minaxi Jhawer Goel Sanjay Wilson J Andrew Montagna Cristina Ling Yi-He Byun Do-Sun Nasser Shannon Arango Diego Shin Joongho Klampfer Lidija Augenlicht H Leonard Soler Perez Roman Mariadason M John: PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab Cancer: Res 2008, 68(6):1953-61. 10.1158/0008-5472.CAN-07-5659 18339877
24. Khan S Kumanagai T Vora J Bose N Sehgal I Koeffler PH Bose S: PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer 2004, 112(3):407-10. 10.1002/ijc.20447 15382065